Arrowhead Pharmaceuticals, Inc.
ARWR
株式のランク
#2462
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
株価
$56.16
最終同期: 2026-10-16
時価総額
$7.93B
変化（1日）
-4.00%
変化（1年）
52.56%
国
US
取引 Arrowhead Pharmaceuticals, Inc. (ARWR)
カテゴリー
Healthcare
Arrowhead Pharmaceuticals, Inc.（ARWR）のEPS
June 2026 時点のEPS TTM: $-2.24
Arrowhead Pharmaceuticals, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-2.24です。2024年末には、EPSは$-5.00で、2023年のEPS$-1.91と増加でした。
Arrowhead Pharmaceuticals, Inc.のEPS履歴（2000から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-2.24 | 22,300.00% |
| 2025 | $-0.01 | -99.76% |
| 2024 | $-5.00 | 161.78% |
| 2023 | $-1.91 | 14.37% |
| 2022 | $-1.67 | 22.79% |
| 2021 | $-1.36 | 61.90% |
| 2020 | $-0.84 | -216.67% |
| 2019 | $0.72 | -210.77% |
| 2018 | $-0.65 | 38.30% |
| 2017 | $-0.47 | -64.93% |
| 2016 | $-1.34 | -16.25% |
| 2015 | $-1.60 | 28.00% |
| 2014 | $-1.25 | -3.85% |
| 2013 | $-1.30 | -31.58% |
| 2012 | $-1.90 | 331.82% |
| 2011 | $-0.44 | -51.11% |
| 2010 | $-0.90 | -78.92% |
| 2009 | $-4.27 | -38.21% |
| 2008 | $-6.91 | -17.25% |
| 2007 | $-8.35 | 40.34% |
| 2006 | $-5.95 | 127.97% |
| 2005 | $-2.61 | 38.83% |
| 2004 | $-1.88 | -84.04% |
| 2003 | $-11.78 | -63.72% |
| 2002 | $-32.47 | 25.03% |
| 2001 | $-25.97 | 33.32% |
| 2000 | $-19.48 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -873.21% |
US
|
|
| $-7.98 | 256.25% |
US
|
|
| $-5.29 | 136.16% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,338.39% |
NL
|
